Abstract
Objectives : The aim of study was to evaluate the use of risk of malignancy index in differentiating benign and malignant ovarian tumours. Materials and methods : 90 women with adnexal mass were included in study. Risk of malignancy index calculated by incorporating ultrasound score, menopausal status and CA 125 level. Sensitivity , specificity , positive predictive value, and negative predictive value were calculated for RMI at different cut off levels in predicting ovarian cancer. Observations : RMI at cut off level 200 seemed to perform better than the individual parameters used seperately. The Sensitivity , specificity , positive predictive value, and negative predictive value of RMI at cut off 200 were 84, 89, 93 and 71% respectively. Conclusion: RMI is a simple, easily applicable scoring system which helps in differentiating benign from malignant ovarian masses pre operatively and aids in timely referral to tertiary centre.
Highlights
Ovarian cancer is one of the leading cause of mortality due to female genital tract malignancy.[1]
The Risk of Malignancy Index (RMI) developed by Jacobs et al is an objective tool based on menopausal status, ultrasound characteristics, and serum CA125 levels; it provides an algorithm that produces quantitative data for the identification of patients with high risk ovarian masses and subsequent referral to cancer center.[4]
RMI was calculated for each patient along with the sensitivity, specificity, positive predictive value and negative predictive values
Summary
Ovarian cancer is one of the leading cause of mortality due to female genital tract malignancy.[1]. 2 Gynaecological cancers have increased in India and are estimated to be around 182,602 by the year 2020 constituting about 30% of the total cancers among women in India. Ovarian cancer being contributing about 19.8% of the total cases.[3] There are no established population-based screening programmes for the disease and few specific symptoms and signs of ovarian cancer. Survival in all cases at 1 year is 55% and at 5 years is 29%. Median survival is 14 months.[1] The Risk of Malignancy Index (RMI) developed by Jacobs et al is an objective tool based on menopausal status, ultrasound characteristics, and serum CA125 levels; it provides an algorithm that produces quantitative data for the identification of patients with high risk ovarian masses and subsequent referral to cancer center.[4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
